Abstract: The method includes providing a filler material that is water insoluble, the providing provides the filler material with more than 98% alpha-cellulose, 0.01% to less than 2% ash and a remainder hemicellulose, infusing at least one first consumable within the filler material and inserting a matrix within at least one first containing structure to form a capsule, the matrix including the filler material.

Abstract: An approach is provided for a segment-based viewing of a watermarked recording. The approach involves receiving a request, from an evaluator, to access one of a plurality of media associated with a plurality of interviewees, wherein each of the plurality of media represents a recording of an interview of a corresponding interviewee; and wherein the request relates to evaluation of the corresponding interviewee for admission or hiring. The approach also involves determining source-identifying information associated with the evaluator. The approach further involves determining source-identifying information associated with the request. The approach additionally involves generating a watermark based on the source-identifying information, wherein the watermark is configured to depict an identifier of the evaluator during a presentation of the requested media. The approach further involves modifying the one media to superimpose the watermark on the recording.

Abstract: An approach is provided for a segment-based viewing of a watermarked recording. The approach involves receiving a request, from an evaluator, to access one of a plurality of media associated with a plurality of interviewees, wherein each of the plurality of media represents a recording of an interview of a corresponding interviewee; and wherein the request relates to evaluation of the corresponding interviewee for admission or hiring. The approach also involves determining source-identifying information associated with the evaluator. The approach further involves determining source-identifying information associated with the request. The approach additionally involves generating a watermark based on the source-identifying information, wherein the watermark is configured to depict an identifier of the evaluator during a presentation of the requested media. The approach further involves modifying the one media to superimpose the watermark on the recording.

Abstract: The present invention relates to methods for treating PCAF mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R3-R6, X, and each Re have any of the values defined in the specification. Also included are novel compounds of formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to methods for treating PCAF mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R3-R6, X, and each Re have any of the values defined in the specification. Also included are novel compounds of formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to compounds of formula (I): and salts thereof, wherein: R1-R4 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of BRG1, BRM and/or PB1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various BRG1-mediated disorders, BRM-mediated disorders and/or PB1-mediated disorders.

Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein R1, R2, Rc, and Rd have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.

Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein R1-R6 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of TAF1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various TAF1-mediated disorders.

Abstract: An approach for providing segment-based viewing of recorded sessions is described. A video platform may determine one or more segments of a communication session based on content of the communication session. The video platform may also associate one or more segments with a recording of the communication session. The video platform may cause, at least in part, a presentation of the recording and one or more indicators for navigating playback of the recording based on the one or more segments, wherein the one or more indicators correspond to the one or more segments.

Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein R1, R2, and Q have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.

Abstract: The present invention relates to methods for treating PCAF and GCN5 mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein ring A, R1, R3, R4, R5, and each Re have any of the values defined in the specification. Also included are novel compounds of Formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein R1, R2, and Q have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.

Abstract: An approach is provided for a segment-based viewing of a watermarked recording. The approach involves storing a plurality of media associated with a plurality of interviewees, wherein each of the plurality of media represents a recording of an unscripted interview of a corresponding interviewee. The approach also involves receiving a request to access one of the plurality of media. The approach further involves determining source-identifying information associated with the request. The approach additionally involves generating a watermark based, at least in part, on the source-identifying information. The approach further involves modifying the one media to superimpose the watermark on the recording. The approach also involves initiating transmission of the modified media to a target device.

Abstract: The present invention relates to compounds of formula (I): and salts thereof, wherein: R1-R4 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of BRG1, BRM and/or PB1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various BRG1-mediated disorders, BRM-mediated disorders and/or PB1-mediated disorders.

Abstract: An approach for providing segment-based viewing of recorded sessions is described. A video platform may determine one or more segments of a communication session based on content of the communication session. The video platform may also associate one or more segments with a recording of the communication session. The video platform may cause, at least in part, a presentation of the recording and one or more indicators for navigating playback of the recording based on the one or more segments, wherein the one or more indicators correspond to the one or more segments.

Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein R1-R6 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of TAF1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various TAF1-mediated disorders.

Abstract: The invention provides a method of inhibiting angiogenesis in a patient by administering a compound of formula (I): wherein R1 R2 and R3 are as defined herein, compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein R1, R2, and Q have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.

Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein R1, R2, Rc, and Rd have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.